Djura P. Piersma

Nieuwegein, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.

Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 14, 2026

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 20, 2026

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

Journal: JAMA oncology

Published: October 16, 2025

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 10, 2025

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 28, 2025

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Journal: British journal of cancer

Published: January 13, 2025

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 28, 2024

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Journal: British journal of cancer

Published: October 04, 2024

PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients.

PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients.

Journal: European urology open science

Published: September 19, 2024

The Effect of Concomitant Immunotherapy and Stereotactic Radiotherapy, and of Location on Survival in Patients With Brain Metastases From Melanoma.

The Effect of Concomitant Immunotherapy and Stereotactic Radiotherapy, and of Location on Survival in Patients With Brain Metastases From Melanoma.

Journal: Cancer medicine

Published: August 01, 2024

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Journal: Immuno-oncology technology

Published: July 24, 2024

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Journal: Cancers

Published: June 28, 2024

Showing 1-12 of 79

Last Updated: 09/26/2026